{'fraction_non_alphanumeric': 0.02406015037593985, 'fraction_numerical': 0.0, 'mean_word_length': 5.66, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Low‐dose weekly paclitaxel for recurrent or refractory aggressive non‐Hodgkin lymphoma

Many patients with recurrent, intermediate or high‐grade non‐Hodgkin lymphoma (NHL) may not respond to or are not candidates for aggressive salvage chemotherapy. Effective, less toxic regimens are needed. Although high‐dose taxanes have not been reported to be very effective for the treatment of lymphoma, different delivery rates may allow for different mechanisms of action to be manifest and result in a different toxicity profile and response rate. The current study tested this hypothesis by using low‐dose, weekly paclitaxel in patients with recurrent or refractory NHL.